论文部分内容阅读
目的观察沙立度胺联合VAD方案治疗初发多发性骨髓瘤(MM)患者的临床疗效和不良反应。方法选择35例初发多发性骨髓瘤患者,采用沙立度胺联合VAD方案进行化疗,每一个疗程为21d,每个疗程之后间歇4周,治疗3个疗程后观察临床疗效及药物的毒副反应。结果治疗3个疗程后,5例患者完全缓解,19例患者部分缓解,进步5例、总有效率为82.8%。毒副反应为骨髓抑制,指端麻木及便秘等。结论沙立度胺联合VAD方案治疗初发MM患者疗效较好,不良反应可以耐受,值得临床推广。
Objective To observe the clinical efficacy and side effects of thalidomide combined with VAD regimen in the treatment of newly diagnosed multiple myeloma (MM). Methods 35 patients with newly diagnosed multiple myeloma were selected and treated with thalidomide combined with VAD. Each course of treatment was 21 days, followed by 4 weeks after each course of treatment. After 3 courses of treatment, the clinical efficacy and drug toxicity reaction. Results After 3 courses of treatment, 5 patients were completely relieved, 19 patients were partly relieved and 5 patients improved. The total effective rate was 82.8%. Side effects of bone marrow suppression, numbness and constipation and other fingers. Conclusion Thalidomide combined with VAD regimen in the treatment of patients with early onset of MM better curative effect, adverse reactions can be tolerated, worthy of clinical promotion.